Report: Current Stock Reports

Ryvu Therapeutics to present recent RVU120 and SEL24 (MEN1703) data at ASCO 2022 Annual Meeting
April 27, 2022

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
April 1, 2022

Ryvu Therapeutics to present recent data from oncology programs at AACR 2022 Annual Meeting
March 8, 2022

Publication dates for periodic reports in 2022
January 19, 2022

Delivery of a lawsuit for payment in connection with the construction of the Research and Development Center
January 19, 2022

Ryvu Therapeutics to receive from Menarini Group a development milestone based on an amended global License Agreement
December 30, 2021

Ryvu Therapeutics receives approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Spain
December 20, 2021

Change order to the statement of work
December 17, 2021

Galapagos NV exercises its exclusive option to license program with therapeutic potential in inflammatory diseases
December 14, 2021

Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology (ASH) Annual Meeting and the 44th San Antonio Breast Cancer Symposium
December 13, 2021

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
November 19, 2021

Ryvu Therapeutics to highlight HPK1 and STING Programs at the upcoming SITC Conference
November 9, 2021

Ryvu’s partner Menarini Group receives FDA Orphan Drug Designation for SEL24 (MEN1703) for the Treatment of Acute Myeloid Leukemia
November 4, 2021

Clinical and Translational Data from RVU120 and SEL24(MEN1703) programs to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the 44th Annual San Antonio Breast Cancer Symposium (SABCS)
November 4, 2021

Filing a lawsuit against Mota-Engil Central Europe S.A. in connection with construction of the Research and Development Center
September 24, 2021

First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors
August 25, 2021

Resignation of the Member of the Management Board
August 25, 2021

Notification from Aviva Otwarty Fundusz Emerytalny Aviva Santander on exceeding the threshold of 5% of the total number of votes in the Company
August 18, 2021

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
August 13, 2021

Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR
July 21, 2021